Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

DRG Diagnostics, BIT Analytical Instruments to launch new product

BIT Analytical Instruments, a complete contract product development, manufacturing services and after-sales service provider to medical and industrial instrument OEM clients, partnered with DRG Diagnostics to launch a revolutionary new product - the DRG:HYBRID XL Analyzer, a fully-automated and integrated random-access analyzer for immunoassays and clinical chemistry.

29 Aug 2012

Wellness Center USA closes PSI acquisition

Wellness Center USA, Inc., a Schaumburg IL based healthcare and nutraceutical company, reported the closing of its Psoria-Shield Inc. (PSI) acquisition. PSI is a Tampa, FL based developer and manufacturer of UltraViolet (UV) phototherapy devices for the treatment of skin diseases.

29 Aug 2012

Human Vaccines & Immunotherapeutics Special Focus provides critical view on cancer vaccines

In one of the most comprehensive peer-reviewed discussions on cancer vaccines and immunotherapeutics, a Special Focus in the journal Human Vaccines & Immunotherapeutics provides a critical view on cancer vaccines and a discussion on best approaches for the future.

28 Aug 2012

United Health Products’ HemoStyp gauze receives CE Mark

United Health Products, Inc., which develops and markets products and technologies in the healthcare sector, today announced that its hemostatic gauze, which is registered and branded in the U.S.A. under the trademark HemoStyp, has been granted use of CE mark which is a mandatory conformity mark for products placed on the market in the European Economic Area (EEA), under the application and registration of its manufacturing agent.

28 Aug 2012

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.

28 Aug 2012

Dartmouth’s professor shares news of DAR-901 TB vaccine development

Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide attributable to a single infectious agent, according to the World Health Organization (WHO). With 8.8 million cases in 2010 and 95 percent of TB deaths occurring in low- and middle-income countries, the disease continues to be a major public health problem in the developing world. In a July address to the International Union Against Tuberculosis and Lung Disease, Dartmouth's C. Fordham (Ford) von Reyn shared news of a promising vaccine in the works.

24 Aug 2012

Lung cells not affected by tiny fibres: Study

Health risks posed to people who work with tiny fibres used in manufacturing industries could be reduced, thanks to new research.

23 Aug 2012

Mylan, Pfizer partner to develop and market generic drugs in Japan

Pfizer Inc. and Mylan Inc. today announced that they have signed a definitive agreement to establish an exclusive long-term strategic collaboration to develop, manufacture, distribute and market generic drugs in Japan. The collaboration is designed to build upon each company's highly complementary strengths and quality assets.

23 Aug 2012

Wockhardt receives final FDA approval for Felodipine ANDA to treat hypertension

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing extended-release tablets containing 2.5mg, 5mg and 10mg Felodipine, which are used in treating hypertension.

22 Aug 2012

Eco-friendly blood glucose monitor developed by Cambridge Consultants

A blood glucose monitor concept for diabetics that’s simpler to use, less cumbersome to carry and has a third of the environmental impact of traditional devices has been developed by Cambridge Consultants.

21 Aug 2012

DPT Labs, Imprimis sign agreement to commence work on Impracor clinical supplies

Imprimis Pharmaceuticals, Inc., a specialty pharmaceutical company developing non-invasive, topically delivered products, announced that it has signed an agreement with DPT Labs to commence work on supplying Imprimis with quantities of its active topical anti-inflammatory drug, Impracor, for currently planned Phase 3 clinical trials.

21 Aug 2012

Molecular Partners, Allergan to develop and commercialize DARPins against ophthalmic diseases

Allergan, Inc. and Molecular Partners AG today announced that they have significantly expanded their existing relationship by entering into two separate agreements to discover, develop, and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases.

21 Aug 2012

UCSF's robots could help dramatically improve efficiency and safety at pharmacies

As Quantum International Corp. scours the globe for new robotics technologies for commercialization, robots now under development at the Medical Center at the University of California San Francisco (UCSF) could soon help dramatically improve efficiency and safety at pharmacies just as they've done in the manufacturing industry.

21 Aug 2012

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem’s Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS’ proprietary EB66® cell line.

20 Aug 2012

Cervical cancer screening: an interview with Alastair Atkinson, CEO of DySIS Medical Ltd

Cervical Cancer is a tragic disease. First and foremost, because it is entirely preventable if the early symptoms are detected in a timely manner

20 Aug 2012

Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial

The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.

16 Aug 2012

Medicine brand choices: an interview with Dr Lynn Weekes

In Australia, people will only be offered a choice when the brands are bioequivalent, meaning they contain the same active ingredient (i.e. the chemical in the medicine that makes it work) and have been proven to work the same in the body.

15 Aug 2012

FDA approves Intelliject's Auvi-Q for anaphylaxis

Intelliject, Inc. announced that the U.S. Food and Drug Administration approved Auvi-Q (epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk or have a history of anaphylaxis. This is the first-and-only compact auto-injector with audio and visual cues that guide patients and caregivers step-by-step through the injection process.

13 Aug 2012

Orally effective FluCide anti-influenza drug candidate

NanoViricides, Inc. announced today that an anti-influenza drug candidate under its FluCide program is effective when given orally. The Company has received information that a FluCide drug candidate designed for oral administration has shown very strong efficacy in corresponding animal studies.

13 Aug 2012

Bristol-Myers Squibb completes acquisition of Amylin

Bristol-Myers Squibb Company and AstraZeneca announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals, now a wholly-owned subsidiary of Bristol-Myers Squibb.

10 Aug 2012